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We investigated whether a recombinant bacteriophage displaying a disease-specific protective epitope could be experi-
mentally used as a vaccine to confer protection of immunized animals against infection. We genetically engineered a
recombinant phage, fd, displaying at its surface a chimeric pIII coat protein fused to the previously identified protective
epitope 173-187 from the glycoprotein G of the human respiratory syncytial virus (RSV). A selected recombinant fd phage
elicited a strong immune response in mice, inducing a high level of circulating RSV-specific antibodies. Mice immunized
with the recombinant phage acquired a complete resistance to RSV infection as evidenced by the lack of detectable virus
particles in their lungs following intranasal challenge with live RSV. In contrast, a high level of virus particles was found in
the lungs of either animals immunized with the wild-type fd phage or nonimmunized mice. To our knowledge, this is the
first study to report the ability of a phage presenting an immunogenic peptide to prevent infection of immunized animals
by a pathogen. This finding should facilitate the identification of pathogen-specific protective epitopes selected from random
phage peptide libraries, as it is simpler and less expensive than the conventional method of synthesis and coupling of
phage-specific peptide ligand sequences for immunization. q 1997 Academic Press
INTRODUCTION tial of the peptide is investigated by the use of a synthetic
peptide representing the peptide ligand sequence (e.g.,
Recently, random peptide libraries displayed on the
Keller et al., 1993; Schellekens et al., 1994; Stoute et al.,
surface of filamentous bacteriophages have been exten-
1995), rather than using the recombinant bacteriophagesively used as a tool to map epitopes or to identify anti-
itself. This is quite surprising since the selected recombi-genic mimics (mimotopes) of disease-specific mono-
nant phage can effectively elicit the production of anti-clonal antibodies or polyclonal sera (Smith, 1985; Par-
bodies specific to the targeted pathogen (de la Cruz etmley and Smith, 1988; Lenstra et al., 1992; Felici et al.,
al., 1988; Greenwood et al., 1991; Willis et al., 1993; Mas-1993; Minenkova et al., 1993; Folgori et al., 1994; Schel-
tico et al., 1993; Minenkova et al., 1993; Zhong et al.,lekens et al., 1994; Motti et al., 1994; Stoute et al., 1995;
1994; Perham et al., 1995; Meola et al., 1995; Loktev etDybwad et al., 1995; Perham et al., 1995; Demangel et
al., 1996; Demangel et al., 1996; Lundin et al., 1996).al., 1996; Lundin et al., 1996). These libraries are engi-
To our knowledge, there is no study reporting that aneered by the insertion of degenerate oligonucleotides,
filamentous recombinant phage which presents a protec-encoding a specific number of random amino acids, in
tive epitope has the ability to protect an experimentalframe with a bacteriophage’s gene specifying a virion
animal model against disease. However, the direct usesurface protein (e.g., Smith, 1985; Parmley and Smith,
of a peptide presenting recombinant phage as a vaccine1988; Haaparanta and Huse, 1995; McConnell et al.,
to examine the peptide’s protective potential would be1996). Following transfection of Escherichia coli, each of
simpler and much less expensive than the conventionalthe infectious phages displays at its surface a fusion
method of peptide synthesis and coupling to a carrierprotein containing a single exogenous small peptide se-
protein for immunization.quence. As a source of novel ligands of very high diver-
The aim of this study was to investigate whether ansity, the bacteriophage display system offers great prom-
epitope presenting recombinant bacteriophage couldise for the development of new effective vaccines di-
protect animals against infection by a target pathogen.rected against specific epitopes of a pathogen. However,
For this purpose, we took advantage of a well-estab-once a disease-specific epitope/mimotope displaying
lished model system based on the ability of a syntheticbacteriophage has been identified, the protective poten-
peptide, representing the amino acid region 173-187 from
the G glycoprotein of the human respiratory syncytial1 To whom correspondence and reprint requests should be
virus (HRSV), to protect immunized BALB/c mice againstaddressed. Fax: (514) 686-5626. E-mail: Claire_Simard@IAF.
UQUEBEC.CA. infection by HRSV (Trudel et al., 1991; Simard et al., 1997).
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We show that immunization of mice with a recombinant mL 3,3-diaminobenzidine (Sigma) prepared in TBS and
containing 0.03% H2O2 .bacteriophage genetically engineered to display the
HRSV-specific epitope induced a strong anti-HRSV im-
Large-scale production of a recombinant phagemune response and conferred complete protection of
animals against RSV infection. These findings thus dem- The recombinant phage 29 was chosen and produced
onstrate that recombinant bacteriophages can be used in large quantities for immunization assays. For this pur-
as vaccines to examine the potential of epitopes of inter- pose, a 2-mL overnight culture of the corresponding E.
est in preventing the corresponding disease in animal coli K802 recombinant colony was grown at 377 in LB
models. medium containing 40 mg/mL tetracycline (LB/tet). Fol-
lowing centrifugation of the culture at 10,000 g for 10
MATERIALS AND METHODS min, 100 mL of the infectious supernatant was used to
infect a 100-mL culture of E. coli K91Kan. The bacterio-Cells and viruses
phage was allowed to adsorb for 10 min at room temper-
The human Long (subgroup A; ATCC VR-26) strain of ature, after which the mixture was added to a flask con-
RSV was propagated on HEp-2 cells (ATCC CCL-23), as taining 20 mL of LB supplemented with 0.2 mg/mL tetracy-
previously described (Trudel et al., 1991). The bacterio- cline. Following a 30-min incubation period at 377, the
phage vector Fuse 5 (Scott and Smith, 1990) was gener- culture was further supplemented with tetracycline at a
ously provided by Dr. G. Smith (University of Missouri, final concentration of 40 mg/mL and incubated for an
Columbia, MO). additional 16 hr. One milliliter of this preculture was used
to subculture 1 L of LB/tet. Following a 16-hr incubation
Engineering of recombinant fd phages displaying the period at 377, the culture was centrifuged as above and
HRSV epitope the infectious phages contained in the supernatant were
precipitated at 47 for 16 hr by the addition of 0.15 vol ofA recombinant fd phage which displays the 173-187
a solution containing 16.7% polyethylene glycol-8000 andamino acid sequence of the HRSV G glycoprotein as a
3.3 M NaCl. After centrifugation, the phage pellet wasfusion to its pIII coat protein was genetically engineered
resuspended in 3 mL of phosphate-buffered saline (PBS;by the in-frame insertion of two complementary oligonu-
Gibco), reprecipitated, and then resuspended in lesscleotides encoding the amino acid sequence of interest
than 1 mL of PBS. The amount of phages produced wasand containing SfiI cohesive ends into the SfiI sites of
estimated by spectrophotometry, where an OD of 1.0 atgene III of the bacteriophage vector Fuse 5 (Fig. 1A). E.
260 nm was assumed to represent 1.0 mg/mL (de la Cruzcoli K802 competent cells were transfected with the DNA
et al., 1988).mixture and then plated onto LB agar plates containing
40 mg/mL tetracycline. Recombinants were identified by
Immunization and protection assaysdideoxy-mediated sequencing using the oligonucleotide
5*-CCCTCATAGTTAGCGTAACG-3*, which complements Five- to six-week-old BALB/c mice were immunized
a region of the fd bacteriophage genome located approxi- three times, at 14-day intervals, by intraperitoneal injec-
mately 85 bases upstream from the DNA insert. tions with 1 mg of wild-type fd, with 1 mg of recombinant
bacteriophage 29, or with 4.8 1 106 PFU of RSV Long
Dot blotting of recombinant bacteriophages strain. The first and subsequent booster doses were
given in the presence of complete and incompleteExpression of the 173-187 HRSV G peptide by phage
Freund’s adjuvant, respectively. Two weeks following therecombinants was assessed by dot blotting of bacterio-
last injection, blood samples were drawn and the seraphage-containing supernatants using a monoclonal anti-
from different animals within a group were pooled forbody (MAb), 18A2B2, which specifically binds to the 174-
performance of ELISA. The following day, animals were187 region of the HRSV G glycoprotein (Trudel et al.,
intranasally challenged with 1.5 1 105 PFU of RSV Long.1991). For this purpose, culture supernatants (200 mL)
Mice were sacrificed 5 days later and their lungs col-containing fd recombinants were blotted onto a PVDF
lected and homogenized at 07 in 10 vol of 199 Hanks’,membrane using a Bio-Dot apparatus (Bio-Rad). The
25 mM HEPES, pH 7.8, 218 mM sucrose, 30 mM MgCl2membrane was incubated for 1 hr at room temperature
containing 0.5 mg/mL fungizone and 50 mg/mL genta-in TBS–Tween (50 mM Tris-HCl, pH 7.5, 150 mM NaCl,
mycin, using a manual homogenizer. After centrifugation0.05% Tween 20) containing 1.5% bovine serum albumin
at 1500 rpm for 15 min, supernatants were collected and(BSA) and then for an additional hour in a fresh solution
tested for the presence of virus by titration assays.containing the MAb 18A2B2. After three washes in TBS –
Tween, the membrane was incubated in TBS-Tween–
ELISA
BSA containing horseradish peroxidase-coupled goat
anti-mouse IgG immune serum (ICN Immunobiologicals, Enzyme-linked immunosorbant assays were per-
formed as previously described (Trudel et al., 1991).Lisle, IL), washed again, and developed with 0.5 mg/
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FIG. 1. (A) Engineering of recombinant bacteriophages displaying the RSV-specific protective epitope. Two complementary oligonucleotides
encoding the amino acid region 173-187 from the G glycoprotein of human RSV and generating SfiI cohesive ends were inserted in frame into the
SfiI sites of the gene III of the bacteriophage vector Fuse 5 (Scott and Smith, 1990). The derived amino acid sequence of the resulting pIII fusion
protein, in the region of interest, is illustrated at the bottom. (B) Dot blotting of recombinant bacteriophages with the MAb 18A2B2. Culture supernatants
containing fd recombinants (29-32) or wild-type phage (fd), as well as protein extracts (1 mg) from purified RSV (RS) or from mock-infected HEp-2
cells (C) were blotted onto a PVDF membrane. The proteins were detected as described under Materials and Methods.
Briefly, proteins (350 ng/well) from purified RS virus or were expressed as log10 TCID50/g of lung (Taylor et al.,
1984).from HEp-2 cells were adsorbed on flat-bottom microtiter
plates overnight at 47. After washing and blocking, 100
mL of serial serum dilutions in PBS containing 10% fetal RESULTS AND DISCUSSION
bovine serum and 0.2% (v/v) Tween 20 was added to
each well and the plates were incubated for 2 hr at 207. We recently reported that immunization of mice with
a synthetic peptide representing the amino acid regionAfter washing, antigen–antibody complexes were re-
acted for 2 hr at 207 with peroxidase-labeled anti-mouse 173-187 of the G glycoprotein of HRSV completely pre-
vents HRSV replication in the lungs of animals (Trudelimmunoglobulin. The reaction was developed with O-
phenylenediamine (0.4 mg/mL in 0.1 M sodium citrate, et al., 1991; Simard et al., 1997). This model system was
used to investigate whether an epitope presenting re-pH 5, containing 0.03% H2O2). Absorbance at 492 nm was
determined using a STL-Labinstrument spectrophotome- combinant bacteriophage could be directly used as a
vaccine to examine the protective potential of the epitopeter (Austria). Titers were expressed as the highest dilu-
tion giving an optical density at least 1.5-fold over back- of interest in preventing disease in animal models. We
thus genetically engineered a recombinant bacterio-ground.
phage displaying the HRSV protective epitope 173-187
as a fusion to its minor coat protein pIII (Fig. 1A). Expres-Titration assays
sion of the 173-187 epitope by the recombinants selected
was assessed by testing the reactivity of bacteriophageTitration assays of lung homogenate supernatants
were carried out in quadruplicate in microtiter plates (24 containing supernatants to the MAb 18A2B2, which spe-
cifically binds to the 174-187 region of the HRSV G glyco-wells) containing confluent HEp-2 monolayer cells. Cul-
ture medium was removed and replaced by 200 mL of protein (Trudel et al., 1991). As shown in Fig. 1B, the
MAb specifically reacted, and to a similar extent, with10-fold serial dilutions of viral supernatants. After a 2-hr
adsorption period at 377 in 5% CO2 atmosphere, 1.5 mL supernatants containing the recombinant phages 29–32
and with protein extracts from HRSV-infected HEp-2of medium containing 199 Hanks’:Earle MEM (1:1), 1%
fetal bovine serum, and 50 mg/mL gentamycin was added cells. In contrast, no reactivity was observed with super-
natants containing either wild-type fd phage or proteinand the plates were incubated for 5 days. Viral titers
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TABLE 1 a putative protective epitope/mimotope is selected from
a random peptide library, it can be directly used in protec-Protective Activity in Mice of the Recombinant Bacteriophage 29
tion assays. This strategy should facilitate and accelerateDisplaying the RSV Protective Epitope 173–187
the identification of a pathogen’s specific protective do-
ELISA titers Protected mains since it is easier and much less expensive than
Immunizationa (log10)b RSV titersc mice/totald the conventional method of chemically synthesizing the
phage-specific peptide ligand of interest followed by itsRecombinant 29 4.2 1.70 8/8
coupling to a macromolecular carrier, the latter being aWild-type fd 1 3.70 { 0.47 0/7
RSV 5.3 1.70 5/5 prerequisite to allow the synthetic peptide to become
Control 1 3.3 { 0.22 0/5 immunogenic. Furthermore, the results obtained herein
offer promise for the use of epitope-presenting recombi-a Mice received three intraperitoneal injections with the recombinant
nant bacteriophages as vaccines, for instance, in veteri-phage 29, the phage fd, or the RSV. The control group represents
nary medicine. These would have the advantage of beingnonimmunized mice.
b ELISA titers are expressed as the highest dilution giving an optical relatively easy to produce in large quantities and would
density 1.5-fold above background. thus be much more cost effective compared to conven-
c Viral titers are expressed as log10TCID50/g of lung; the detection tional vaccines.
limit was 101.7. Standard deviations of the mean are indicated.
d Number of mice with no detectable virus in their lungs 5 days
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demonstrate that the bacteriophage recombinants se-
lected displayed the 173-187 amino acid region of the
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